NSE · AATMAJ
Aatmaj Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹25 Cr with net profit ₹1 Cr — a 2.82% net margin, versus 3.07% the period before.
Shareholding
As of 2026-03-31
- Promoter64.33%
- Public35.67%
1,288 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.53× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #46 of 85 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,27,048 Cr | 60.38 | 13.42 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,01,000 Cr | 67.47 | 9.4 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹94,359 Cr | 100.61 | 5.73 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹67,025 Cr | 62.83 | 6.77 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,652 Cr | 171.83 | 15.81 | 8.48% | 6.54% |
| Global Health Limited | ₹38,911 Cr | 67.98 | 9.82 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹38,199 Cr | 44.31 | 8.41 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,296 Cr | 154.72 | 8.62 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,042 Cr | 56.97 | 12.78 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,613 Cr | 55.04 | 5.67 | 10.37% | 15.77% |
| Aatmaj Healthcare Limited(this company) | ₹42 Cr | 58.13 | 0.83 | 1.4% | 21.83% |
AI analysis
AI-generated · google/gemini-2.5-flashAatmaj Healthcare Limited had a market capitalization of Rs 41 Cr. The company's revenue was Rs 20.85 Cr and it reported an EPS of Rs 0.32. The promoter holding stood at 64.3274% as of March 31, 2026. The price-to-earnings ratio is 228.13.
Positives
- +The company's debt-to-equity ratio is low at 0.16.
- +Promoter shareholding is substantial at 64.3274% as of March 31, 2026.
- +Promoter pledging is 0%.
Negatives
- −The profit margin for the latest period is 0%.
- −Net profit has decreased from Rs 5.9065 Cr in Mar 2023 to Rs 0.6393 Cr in Mar 2025.
- −Annual revenue decreased from Rs 27.189 Cr in Mar 2023 to Rs 16.5849 Cr in Mar 2024.
- −The price-to-earnings ratio is high at 228.13.
- −Return on capital employed is low at 3.2621%.
Financial Performance
Aatmaj Healthcare Limited reported revenue of Rs 20.85 Cr in the most recent period. The company's diluted EPS was Rs 0.32. Over recent years, annual revenue has fluctuated, reaching Rs 27.189 Cr in Mar 2023 before decreasing to Rs 16.5849 Cr in Mar 2024 and then increasing to Rs 20.8501 Cr in Mar 2025. Annual net profit also saw variation, with a high of Rs 5.9065 Cr in Mar 2023, declining to Rs 0.8808 Cr in Mar 2024 and further to Rs 0.6393 Cr in Mar 2025.
Profitability & Returns
The company reported a return on equity (ROE) of 140.3% and a return on capital employed (ROCE) of 3.2621%. The profit margin for the latest period was 0%. Annual net profit declined from Rs 5.9065 Cr in Mar 2023 to Rs 0.6393 Cr in Mar 2025. Earnings per share also decreased from Rs 3.64 in Mar 2023 to Rs 0.28 in Mar 2025.
Balance Sheet
Aatmaj Healthcare Limited maintains a debt-to-equity ratio of 0.16, indicating a relatively low reliance on debt financing. The book value per share is Rs 22.49. There are no reported pledged shares by the promoters.
Ownership & Pledges
As of March 31, 2026, the promoter holding in Aatmaj Healthcare Limited was 64.3274%. Public shareholding was 35.6726%. There was no reported FII or DII holding. The number of shareholders was 1288. Promoter pledge is reported as 0%.
Regulatory & Surveillance
The company is not currently listed under any surveillance measures. There is no information available regarding specific regulatory actions.
Data as of — price: 2026-09-12 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.